COLEC10

Chr 8

collectin subfamily member 10

Also known as: 3MC3, CL-10, CL-34, CLL1

NCBI Gene: 10584 ENSG00000184374 UniProt: Q9Y6Z7

This gene encodes a cytosolic lectin that binds to various sugars and acts as a chemoattractant involved in regulating cell migration. Mutations cause 3MC syndrome 3, a developmental disorder with craniofacial, skeletal, and other congenital anomalies. The condition follows autosomal recessive inheritance.

ResearchSummary from RefSeq, OMIM, UniProt

This gene encodes a member of the C-lectin family, proteins that possess collagen-like sequences and carbohydrate recognition domains. The other members of this family are secreted proteins and bind to carbohydrate antigens on microorganisms facilitating their recognition and removal. This gene product is a cytosolic protein, a characteristic that suggests that it may have different biological functions than other C-lectins. [provided by RefSeq, Jul 2008]

ResearchGenerating clinical summary…

Primary Disease Associations & Inheritance

UniProt3MC syndrome 3

Clinical highlights

Interpreting a novel variant

Loss of function is the curated mechanism (Gene2Phenotype), though the gene is not strongly LoF-constrained in the population — weigh truncating variants against that tolerance.Curated gene-level mechanism — a prior for triage, not a per-variant call.

Active trials

Pubs (1 yr)

—

P/LP submissions

—

P/LP missense

0.96

LOEUF

LOF

Mechanism· G2P

Some data sources returned errors (1)

omim: Error: OMIM fetch failed: 429

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

gnomAD

Tolerant — LoF & missense variants common in population

LoF Constraint?

0.96LOEUF

pLI 0.003

Z-score 1.66

OE 0.49 (0.27–0.96)

Tolerant

Typical tolerance to LoF variation

Missense Constraint?

0.03Z-score

OE missense 0.99 (0.87–1.13)

158 obs / 159.0 exp

Tolerant

Mild missense constraint

Observed / Expected Ratios?

LoF OE?0.49 (0.27–0.96)

0≤0.351.4

Missense OE?0.99 (0.87–1.13)

0≤0.61.4

Synonymous OE?0.88

0≤1.21.6

LoF obs/exp: 6 / 12.3Missense obs/exp: 158 / 159.0Syn Z: 0.71

ClinVar Variant Classifications

0 submitted variants in ClinVar

ClinVar

Protein Context — Lollipop Plot

COLEC10 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

External Resources

Links to major genomics databases and tools

Franklin by Genoox

AI-powered variant curation and clinical analysis

DECIPHER

Genomic variants and phenotypes in rare disease patients

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

ClinicalTrials.gov

Acute Myeloid Leukemia

A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

RECRUITING

NCT06880354Phase PHASE1Institute of Hematology & Blood Diseases Hospital, ChinaStarted 2025-05-22

CLL1 and CD38 Dual-Target CAR-T Cell Injection

Acute Myeloid Leukemia

Chimeric Antigen Receptor T-cells for The Treatment of AML Expressing CLL-1 Antigen

ACTIVE NOT RECRUITING

NCT04219163Phase PHASE1Baylor College of MedicineStarted 2020-07-09

CLL-1.CAR T cells

Acute Myeloid Leukemia (AML)

Anti-CD33-CLL1 CAR-T Cells (ICG415) for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

RECRUITING

NCT07668557Phase PHASE1iCell Gene TherapeuticsStarted 2026-06-10

Anti-CD33-CLL1 CAR-T cells (ICG415) following lymphodepleting fludarabine and cyclophosphamide

Acute Myeloid LeukemiaChimeric Antigen Receptor T-cellUniversal CLL1 CAR-T

Clinical Study on the Safety, Efficacy and Pharmacokinetics of Universal CLL1 Chimeric Antigen Receptor T-Cell in Relapsed/Refractory Acute Myeloid Leukemia

NOT YET RECRUITING

NCT07432100Phase PHASE1Mingfeng ZhaoStarted 2026-02

universal CLL1 CAR-T cells

LeukemiaAcute Myeloid Leukemia

BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia in Children

NOT YET RECRUITING

NCT06347458Phase PHASE1Guangzhou Bio-gene Technology Co., LtdStarted 2024-04

BG1805

Acute Myeloid Leukemia

Multi-CAR T Cell Therapy for Acute Myeloid Leukemia

NOT YET RECRUITING

NCT03222674Phase PHASE1, PHASE2Shenzhen Geno-Immune Medical InstituteStarted 2026-12-31